2025-10-11 - Analysis Report
Okay, here's an analysis of TransMedics Group Inc. (TMDX) based on the provided data, formatted for a clear and concise English report.

## TransMedics Group Inc. (TMDX) Analysis

**Company Overview:** TransMedics Group Inc. is a medical technology company focused on preserving and assessing organs for transplant.

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 171.42%
*   **VOO Cumulative Return:** 74.32%
*   **Absolute Divergence:** 120.9
*   **Relative Divergence:** 60.7

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO) over the period examined.  The relative divergence of 60.7 indicates that TMDX's outperformance is positioned at the 60.7th percentile of its historical divergence range compared to VOO. It means the outperformance isn't at its peak historically but is still substantial.

**Alpha, Beta Analysis**

| Year       | CAGR      | MDD   | Alpha    | Beta   | Cap(B) |
|------------|-----------|-------|----------|--------|--------|
| 2019-2021  | -18.0%    | 83.5% | -61.0%   | -0.0   | 0.7    |
| 2020-2022  | 94.0%     | 83.5% | 95.0%    | 0.0    | 2.1    |
| 2021-2023  | 65.0%     | 80.5% | 64.0%    | 0.1    | 2.7    |
| 2022-2024  | 130.0%    | 85.5% | 109.0%   | 0.1    | 2.1    |
| 2023-2025  | 92.0%     | 85.5% | 29.0%    | 0.3    | 3.7    |

**Analysis:**

*   **CAGR:**  CAGR is high, especially in the periods 2020-2022, 2022-2024, and 2023-2025, indicating strong growth rates.
*   **MDD:** High MDD values suggest significant volatility and potential for substantial drawdowns.
*   **Alpha:** The consistently positive Alpha values, particularly high in 2020-2022 and 2022-2024, indicate the stock's ability to generate returns above the benchmark.
*   **Beta:** The Beta values are generally low, suggesting the stock is not closely correlated with the overall market.
*   **Cap(B):** Market capitalization has been growing over the past few years.

### 2. Recent Stock Price Movement

*   **Current Price:** 108.36
*   **Last Market Data:** Price: 108.355, Previous Close: 112.98, Change: -4.09
*   **5-day Moving Average:** 114.244
*   **20-day Moving Average:** 116.2763
*   **60-day Moving Average:** 115.6867

**Analysis:** The current price is below all three moving averages (5, 20, and 60-day), suggesting a short-term downward trend. The recent price drop of -4.09 from the previous close reinforces this observation, indicating potential selling pressure.

### 3. Technical Indicators and Outlook

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 31.03 (Approaching Oversold)
*   **PPO:** -0.3055
*   **Hybrid Signal:** "cash\_0% Buy 100% of cash (8 shares - Very Safe - MRI:0.90)"
*   **Recent (20-day) Relative Divergence Change:** 2.0 (+) Short-term Rise
*   **Expected Return:** 49.4% (Over S&P 500, Long-Term)

**Analysis:**

*   **MRI:** The MRI suggests a high investment recommendation, indicating a favorable risk/reward profile.
*   **RSI:** The RSI is close to the oversold territory (typically below 30), which *could* signal a potential buying opportunity, although it can also indicate sustained downward momentum.
*   **PPO:** The PPO is negative, suggesting the short-term moving average is below the long-term moving average, confirming the recent downward trend seen with the moving averages in section 2.
*   **Hybrid Signal:**  The hybrid signal is strongly bullish, recommending full investment (0% cash).
*   **Recent Relative Divergence Change:** The recent increase in relative divergence indicates a potential short-term upward trend.
*   **Expected Return:** The high expected return (49.4% above the S&P 500 over the long term) is a very positive signal, suggesting strong confidence in the company's future growth.
*   **Price Change Impact:** Given the significant price change (down 4.09), it's crucial to understand the catalyst. Was it a company-specific event, sector-wide issue, or broader market correction?

### 4. Recent News & Significant Events

*   **Positive Growth Coverage:** Multiple articles highlight the company's growth and potential.
*   **Analyst Recognition:**  Features as a "Strong Growth Stock" and inclusion in lists of stocks to "Buy and Hold for a Decade" are very positive.
*   **Mercedes-Benz Partnership:** The organ transport partnership with Mercedes-Benz is a significant strategic development, indicating innovation and expansion into new markets.
*   **Potential Undervaluation:**  Coverage suggests the stock may be undervalued.

**Key Takeaways:** The news flow is overwhelmingly positive, focusing on growth, strategic partnerships, and potential undervaluation.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (1.82 on a 1-5 scale)
*   **Target Price:** Average 140.67, High 170.00, Low 114.00

**Analysis:** Analyst sentiment is strongly positive, with a consensus "Buy" rating and a significant average target price well above the current price. The low target price is still higher than the current price, reinforcing the potential for upside.

### 5. Recent Earnings Analysis

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-07-30 | 0.92 | 0.48         |
| 2025-05-08 | 0.7  | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |

**Analysis:** TransMedics has consistently exceeded EPS expectations in recent quarters. This strong earnings performance is a positive indicator of the company's financial health and operational efficiency. The 2024-10-28 data, where EPS fell short of expectations, should be investigated further to understand the reasons behind the underperformance.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.16B  | 61.38%        |
| 2025-03-31 | $0.14B  | 61.47%        |
| 2024-12-31 | $0.12B  | 59.21%        |
| 2024-09-30 | $0.11B  | 55.94%        |
| 2024-06-30 | $0.11B  | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE     |
|------------|---------|---------|
| 2025-06-30 | $0.32B  | 10.97%  |
| 2025-03-31 | $0.27B  | 9.64%   |
| 2024-12-31 | $0.23B  | 3.00%   |
| 2024-09-30 | $0.21B  | 2.01%   |
| 2024-06-30 | $0.19B  | 6.42%   |

**Analysis:**

*   **Revenue:**  Revenue is consistently growing, indicating increasing demand for TransMedics' products and services.
*   **Profit Margin:**  High and relatively stable profit margins demonstrate strong operational efficiency and pricing power.
*   **Equity:**  Equity is increasing, suggesting the company is retaining earnings and building its asset base.
*   **ROE:** ROE has shown positive growth, indicating the company's ability to generate profits from its equity investments.

### 7. Overall Assessment

Based on the provided data, TransMedics Group Inc. (TMDX) presents a compelling investment case:

*   **Strong Performance:** Significant outperformance compared to the S&P 500, positive alpha values, indicating superior risk-adjusted returns.
*   **Positive Momentum:**  Recent positive news, analyst upgrades, and strong earnings results.
*   **Solid Fundamentals:** Increasing revenue, high-profit margins, and growing equity.
*   **Bullish Signals:** High MRI score, positive hybrid signal, and a substantial long-term expected return.
*   **Risks:** Recent price drop warrants further investigation. The company's stock is currently below its moving averages.

**Conclusion:** While the recent price dip requires attention and the volatility indicated by the MDD should be acknowledged, the overall picture for TMDX is positive. The company's strong growth, positive analyst sentiment, and promising financial metrics suggest potential for future gains, especially with a long-term investment horizon. A closer look at the reasons behind the recent price decline and a careful consideration of individual risk tolerance are essential before making an investment decision.
